Batch manufacture of high titer/titre GMP (U.S.A.) compliant lentiviral vector for FDA approval
We are planning a phase I/II clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy will use autologous CD34+ haematopoietic stem progenitor cells (HSPCs) which are modified ex vivo with LVV to express supraphysiologic levels of a secreted enzyme. In order to progress this therapy, we require a high titre LVV produced to good manufacturing practice (GMP) standard. The supplier must have extensive previous experience manufacturing LVVs to this specification which hav...
Buyer
University Of Edinburgh
Value
£900,000
Published
30 Jul 2025
Closes
1 Sept 2025
Procurement details
Source
Pcs
Region
United Kingdom
Procurement method
Selective
Category
Services
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
85121200
Medical specialist services
Lots
Lot 1 Batch manufacture of high titer/titre GMP (U.S.A.) compliant lentiviral vector for FDA approval
£900,000
See procurement documentation for all un-abridged description. DEFINITIONS FDA is the U.S Food and Drug Administration (FDA); the regulator for new clinical drugs GMP means ‘Good Manufacturing Practice’; U.S.A. IND is an “Investigational New Drug Application”; a request to the FDA to be permitted to administer a new prototype drug on human patients for resea...
Delivery: UKM75, US
Documents
Unlock document linkBatch manufacture of high titer/titre GMP (U.S.A.) compliant lentiviral vector for FDA approval
Not provided
We are planning a phase I/II clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy will use autologous CD34+ haematopoietic stem progenitor cells (HSPCs) which are modified ex vivo with LVV...
Contract notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.